The Indian Pharmacopoeia Commission (IPC) is set to become the first WHO Collaborating Centre for Safety of Medicines and Vaccines in the South-East Asia Region.
This was stated by Shri J P Nadda, Union Minister of Health and Family Welfare while addressing the 38th Annual Meeting of Representatives of the National Pharmacovigilance Centres participating in the World Health Organization Programme for International Drug Monitoring, organized by the Indian Pharmacopoeia Commission (IPC) and World Health Organization (WHO).
Meeting is hosted annually by one of the WHO Member States. The annual meeting of National Pharmacovigilance Centres acts as a platform for countries to discuss current issues and concerns in pharmacovigilance. More than 150 international delegates from over 57 countries are attended this meeting.
Drug safety related issues pose a major challenge for healthcare professionals, regulators and pharmaceuticals industry and this is where Pharmacovigilance, plays a significant role in ensuring quality, safety and efficacy of medical products.
The Minister applauded the WHO collaborating centres across the globe which serve as platforms for knowledge transfer and act as catalysts for developing the next level good pharmacovigilance practices and awareness of adverse drug reactions and their reporting.
Establishment of a robust pharmacovigilance system and increasing its reach, quality and credibility is vital for development of safe medical products.
India is committed to ensuring patient safety in the country and to building strong working relations with other countries with respect to healthcare system, including pharmacovigilance system.
Government of India launched the Pharmacovigilance Programme in 2010 to address the impact of Adverse Reactions on patients. This programme has created a nation-wide system for patient safety reporting, to identify and analyse risk benefit ratio of marketed medicines, to generate evidence on safety of medicines and to support regulatory agencies in decision making.
These efforts have gained momentum after the Indian Pharmacopoeia Commission was notified as the National Coordination Centre for pharmacovigilance.
To monitor Adverse Drug Reactions, Pharmacovigilance Programme of India has set up 179 Centres.
Adverse Drug Reactions are reported to Indian Pharmacopoeia Commission, which works in collaboration with global Adverse Drug Reaction monitoring centre, Sweden to contribute to the global Adverse Drug Reactions data base.
India is also in the process of implementing free drugs initiatives across the country so that those who cannot afford are able to get the high quality drugs.